The management of visceral leishmaniasis (VL) in HIV-infected patients is complex because of high mortality rates, toxic drug-related side effects, and a high risk of treatment failure and relapse. We report a case of active chronic VL in an HIV-1-infected woman presenting multiple secondary VL episodes over 7 years leading to massive splenomegaly and blood transfusion-dependent anemia despite several treatment courses and secondary prophylaxis. The patient was finally successfully treated with rescue treatment based on intravenous pentamidine. Twenty months after discontinuation of pentamidine the patient presented complete clinical and parasitological response. In patients with active chronic VL, treatment with intravenous pentamidine can be effective and should be considered as rescue treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832899 | PMC |
| http://dx.doi.org/10.4269/ajtmh.21-0600 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Clin Microbiol Infect
December 2024
BioTechMed-Graz, Graz, Austria; Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Background: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP.
Objectives: The objectives of this study are to compare the efficacy (treatment failure and mortality) and tolerability (treatment change) of PCP treatment regimens with a frequentist network meta-analysis.
Variance in Pneumocystis jirovecii prophylaxis practice for pediatric patients undergoing hematopoietic cell transplantation.
Pediatr Blood Cancer
October 2024
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pneumocystis jirovecii pneumonia (PJP) in hematopoietic cell transplant (HCT) recipients can be prevented by efficient prophylaxis. We surveyed HCT centers in North America to assess their PJP prophylaxis practices. Most institutions used intravenous (IV) pentamidine (29.
View Article and Find Full Text PDFA retrospective study of intravenous pentamidine for Pneumocystis jirovecii pneumonia prophylaxis in adult patients with hematologic malignancies-its utility during respiratory virus pandemics.
Int J Infect Dis
June 2024
Singhealth Duke-NUS Transplant Centre, Singapore; Singhealth Duke-NUS Medicine Academic Clinical Programme, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore. Electronic address:
Objectives: In hematology, prophylaxis for Pneumocystis jirovecii pneumonia (PCP) is recommended for patients undergoing hematopoietic stem cell transplantation and in selected categories of intensive chemotherapy for hematologic malignancies. Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line agent; however, its use is not straightforward. Inhaled pentamidine is the recommended second-line agent; however, aerosolized medications were discouraged during respiratory virus outbreaks, especially during the COVID-19 pandemic, in view of potential contamination risks.
View Article and Find Full Text PDFEvaluation of pentamidine tolerability and efficacy between phenotypes.
Pharmacogenomics
October 2023
Specialty Pharmacy Services, Atrium Health, Charlotte, NC 28204, USA.
Intravenous pentamidine is used for prophylaxis against pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by , which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as pneumonia prophylaxis.
View Article and Find Full Text PDFIn Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis.
Pharmaceutics
April 2023
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, Spain.
Article Synopsis
- Pentamidine, an antileishmanial drug, is typically given through injection but has serious side effects like diabetes and renal toxicity, which limit its use.
- Researchers tested phospholipid vesicles (liposomes) to enhance the efficacy and patient compliance of pentamidine via aerosol therapy, finding that coated liposomes improved targeting to infected macrophages and reduced cytotoxicity.
- The study revealed that nebulized liposome-encapsulated pentamidine significantly increased drug deposition in the lungs and could provide a more effective and self-administered treatment option for leishmaniasis and other related infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!